GENITOURINARY CANCER—PROSTATE, TESTICULAR, AND PENILE

TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).Read more..

 7
GENITOURINARY CANCER—PROSTATE, TESTICULAR, AND PENILE